Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Delivery
- Pharmaceuticals
- Pain
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2913
License Grant
The United Kingdom Company terminated the License Agreement with the Licensee for Amlexanox related products in the United Kingdom and Ireland. On November 17, 2008, the Company conveyed the Amlexanox related product rights to the United Kingdom and Ireland territories to MEDA AB.
License Property
NanoflexTM technology provides unique materials with a broad range of properties and potential applications. While a conventional bulk hydrogel is an infinite network of loosely cross-linked hydrophilic polymers that swells when placed in polar solvents, we have discovered that a variety of unique biomaterials can be formed through the aggregation of hydrogel – like nanoparticles. This concept takes advantage of the inherent biocompatibility of hydrogels while overcoming problems with local stress and strain, which cause bulk hydrogels to shear. Unlike bulk hydrogels, these particle aggregates are shape retentive, can be extruded or molded, and offer properties suitable for use in a variety of in-vivo medical devices, and in novel drug delivery systems, by providing tailored regions of drug incorporation and release. The polymers used in our NanoflexTM technology have been extensively researched by the academic and scientific community and commercialized into several major medical products. They are generally accepted as safe, non-toxic and biocompatible.
OraDisc™ is a novel erodible muco-adhesive film product. This technology, known as OraDisc™, comprises a multi-layered film having an adhesive layer, a pre-formed film layer, and a coated backing layer. Depending upon the intended application, a pharmaceutically active compound can be formulated within any of these layers, providing a wide range of potential applications. The disc stays in place eroding over a period of time, so that subsequent removal is unnecessary. The drug delivery rate is pre-determined by the rate of erosion of the disc, which is in turn controlled by the composition of the backing layer. OraDisc™ was initially developed as a drug delivery system to treat canker sores with the same active ingredient (amlexanox) that is used in our Aphthasol® paste.
Field of Use
The Company (Licensee) is a diversified specialty pharmaceutical company committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products based on our patented NanoflexTM and OraDiscâ„¢drug delivery technologies, with the goal of improving outcomes for patients, health care professionals, and health care payers.
IPSCIO Record ID: 3211
License Grant
Licensor hereby grants to Licensee of Korea, an exclusive license in and to the use of the Licensed Technology including the right to sublicense any or all of such rights in accordance with the terms of this Agreement to make, have made, use, offer for sale and sell Products in the Territory.
License Property
Licensed Technology shall mean all Patent Rights and all technical information and data owned, possessed, or reasonably obtainable from Innozen by Licensor as of the date of this Agreement relating to the development, manufacture including manufacturing process, and commercialization of Products, but only to the extent such information and data is reasonably necessary to commercially exploit the Products within the Territory.
Patent Applications shall mean United States non-provisional patent application U.S. Serial No. 10/713,544 filed in the USPTO, Europe, Canada, Mexico and Japan on November 14, 2003 and United States non-provisional patent application U.S. Serial No. 10/402,273 filed in the USPTO, Europe and Canada on March 28, 2003; all United States and foreign patents and patent applications deriving priority from the Provisional Applications, and any divisions, continuations, continuations-in-part, re-examinations and reissues of such patent applications.
IPSCIO Record ID: 203466
License Grant
Licensor grants the exclusive right and license in the Field under Licensors Intellectual Property Rights to market, offer for sale, sell and import products, including the Product, in the Territory, the exclusive right and license in the Field under Licensors Intellectual Property Rights to use the Product in the Territory, provided that such right and license is limited to such use as is necessary for Licensee to market, offer for sale, sell, import and, Manufacture the Product in the Territory, and a non- exclusive right and license to use the Product and all information and Intellectual Property Rights with respect thereto, including, without limitation, data, studies and clinical trials, solely for the purpose of obtaining Regulatory Approvals for the Product.
Licensor grants an exclusive, non-transferable, except in accordance with a permitted assignment of this Agreement, license in the Field to use Licensors trademark.
License Property
Licensor is developing a proprietary oral mucoadhesive, erodible form of drug that contains benzocaine as the active ingredient for oral pain.
The Licensors trademark is ORADISC.
Field of Use
The Field means the treatment of oral pain utilizing anesthetics, excluding the treatment of sore throat and excluding any product containing amlexanox as an active ingredient.
IPSCIO Record ID: 372482
License Grant
Licensor grants an exclusive, including with respect to Licensor except as to Licensor’s performance of its obligations under this Agreement or conduct of the Existing Clinical Trials, license, with the right to sublicense, in the Field in the Territory, under the Licensor Intellectual Property, to develop, make or have made, use, offer for sale, sell, import, market and promote Product.
For the Licensor Trademarks, Licensor grants an exclusive, including with respect to Licensor except as to Licensor’s performance of its obligations under this Agreement and conduct of Existing Clinical Trials, license, with the right to sublicense, to use the Licensor Trademarks solely in connection with Product in the Territory.
License Property
The patents relate to
Transmucosal delivery devices with enhanced uptake;
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces; and,
Transmucosal drug delivery for use in chronic pain relief.
Licensor controls certain patents and know-how relating to Product, and has initiated clinical studies with respect to the Product.
The Active Ingredient means buprenorphine. Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.
Product means a drug product containing buprenorphine as its sole active ingredient (and not containing naloxone or any analog or derivative thereof and using Licensors BEMA Technology in any formulation and any dosage strength.
BEMA Technology means Licensor’s proprietary BioErodible MucoAdhesive (BEMA®) Drug Delivery Technology, a buccal soluble film consisting of a small bioerodible polymer film for application to the mucosal membranes (inner lining of the cheek).
Field of Use
The Field means all uses in humans. Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
